Abstract
BackgroundBreast cancers have shown limited responses to current FDA approved forms of immunotherapy. Defective antigen presentation in breast cancers contributes to this deficient anti-tumor immunity. Flt3 ligand (Flt3L) is a...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
